- Published at
- by gurufocus.com
positive
positive
News for Appili Therapeutics Inc. (APLIF)
- Published at
- by gurufocus.com
positivepositiveAditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
Aditxt, Inc. (NASDAQ: ADTX) (”Aditxt” or the ”Company”), a social innovation platform accelerating promising health innovations, announced that today's- Published at
- by gurufocus.com
positivepositiveUpcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
Aditxt, Inc. (NASDAQ: ADTX), (”Aditxt” or the ”Company”), a social innovation platform accelerating promising health innovations, announced that today'- Published at
- by gurufocus.com
positivepositiveAppili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Four new funding proposals, totalling US$117.5 million, have been submitted for reviewModifications received to U.S. Air Force Academy Cooperative AgreementOuts- Published at
- by gurufocus.com
positivepositiveAditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovation- Published at
- by gurufocus.com
positivepositiveAditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025
Aditxt, Inc. (NASDAQ: ADTX) (”Aditxt” or the ”Company”), an innovation platform dedicated to discovering, developing, and deploying promising health in- Published at
- by gurufocus.com
positivepositiveAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on- Published at
- by financialpost.com
positivepositiveAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt- Published at
- by investing.com
mixedmixedADTX stock plunges to 52-week low, touches $0.18 By Investing.com
ADTX stock plunges to 52-week low, touches $0.18- Published at
- by gurufocus.com
positivepositiveAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt, Inc. (NASDAQ: ADTX) (”Aditxt” or the ”Company”), a social innovation platform dedicated to accelerating promising health innovations, today ann- Published at
- by financialpost.com
neutralneutralAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt- Published at
- by financialpost.com
positivepositiveAppili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES- Published at
- by investing.com
positivepositiveAppili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024 By Investing.com
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024- Published at
- by financialpost.com
neutralneutralAppili Therapeutics – Press Release Correction
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to it…- Published at
- by investing.com
positivepositiveAditxt moves to acquire Appili Therapeutics By Investing.com
Aditxt moves to acquire Appili Therapeutics- Published at
- by investing.com
positivepositiveAditx Therapeutics stock hits 52-week low at $1.58 By Investing.com
Aditx Therapeutics stock hits 52-week low at $1.58- Published at
- by financialpost.com
positivepositiveAditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
MOUNTAIN VIEW, Calif. — Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promisi…- Published at
- by investing.com
mixedmixedAditxt shareholders approve strategic proposals By Investing.com
Aditxt shareholders approve strategic proposals- Published at
- by globenewswire.com
positivepositiveGlobal Infectious Disease Testing Products Market to Reach US$ 46.4 Billion by 2030 with a CAGR of 6.7%: Product, Testing Type, End User, and Regional Analysis
According to the latest research report published by DataM Intelligence, the Global Infectious Disease Testing Products Market was valued at US$ 27.8...- Published at
- by globenewswire.com
mixedmixedBiodefence Market is projected to grow at a CAGR of 7.78% by 2033: Visiongain Reports Ltd
Visiongain has published a new report entitled Biodefence Market 2023-2033. It includes profiles of Biodefence Market and Forecasts, Market Segment by Size...